Lyndra Therapeutics appoints Adam Sayer as new president and CEO

USA—Lyndra Therapeutics®, a clinical-stage biopharmaceutical company specializing in long-acting oral therapies, has appointed Adam Sayer as its new President and Chief Executive Officer, effective immediately.

In addition to his new role, Sayer will also serve on the company’s Board of Directors.

Sayer joins Lyndra from Envision Healthcare, where he served as Chief Transformation Officer, leading strategy, business transformation, and payer negotiations.

With extensive experience in the healthcare industry and a strong track record of operational success, he is expected to play a key role in advancing Lyndra’s lead program—oral weekly risperidone (LYN-005)—and driving the company’s mission to bring the first-ever long-acting oral therapeutics to patients.

Expressing his enthusiasm about the new role, Sayer highlighted the potential of Lyndra’s LYNX® platform technology, which has demonstrated a promising ability to revolutionize oral medicine delivery and improve patient outcomes.

He stated that he is eager to lead Lyndra’s talented team as they work toward bringing long-acting oral treatments to market.

Sayer succeeds Jessica Ballinger, who has served as Lyndra’s President and CEO and played a crucial role in the company’s growth.

Under her leadership, Lyndra successfully completed the pivotal efficacy study for LYN-005 and formed a strategic collaboration with Thermo Fisher Scientific for global clinical research and commercial manufacturing.

Ballinger remarked that she is incredibly proud of the team’s accomplishments during her tenure at Lyndra, including the creation and testing of the LYNX® platform, the successful completion of their lead program’s first trial, and the acquisition of a significant manufacturing partnership.

She expressed confidence that the company is well-positioned for continued success.

Lyndra’s co-founder and Executive Chair of the Board, Amy Schulman, also acknowledged Ballinger’s contributions, stating that they are grateful for her dedication to the company’s mission.

She added that with Adam Sayer’s leadership and strong focus on execution, Lyndra is now well-equipped to achieve its goals and transform the way oral medicines are delivered.

Looking ahead, the company is preparing to launch a pivotal safety study for LYN-005 in the first half of 2025.

This study will be a significant step toward bringing long-acting oral risperidone to market, potentially offering a new treatment option for patients who require sustained medication delivery.

Sign up HERE to receive our email newsletters with the latest news and insights from Africa and around the world, and follow us on our WhatsApp channel for updates.

Newer Post

Thumbnail for Lyndra Therapeutics appoints Adam Sayer as new president and CEO

Takeda appoints Julie Kim as successor to CEO Christophe Weber

Older Post

Thumbnail for Lyndra Therapeutics appoints Adam Sayer as new president and CEO

M42 , RMS partner to advance organ transplantation in the region

Be the first to leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.